Small Scale Bioreactors Market Analysis & Forecast: 2026-2033

Small Scale Bioreactors Market Size and Forecast – 2026 to 2033

The Small Scale Bioreactors Market is anticipated to grow at a CAGR of 9.2% with USD 2.1 Bn in 2026 and is expected to reach USD 2.9 Bn in 2033. Rising biopharmaceutical R&D drives growth, while expanding cell and gene therapy development strengthens demand.

The Union Budget 2026–27 signals a strategic shift in India’s pharmaceutical policy by prioritizing biopharma and biologics, aligning with the Government of India’s goal of positioning the country as a global biopharma leader.

Key Takeaways

• Reusable Bioreactors hold the largest market share of 53.3% in 2026 owing to the expansion of pharmaceutical R&D and drug development. Global pharmaceutical R&D expenditure has nearly doubled since 2016, reaching approximately US$300 billion in 2025.
• 5 ML-100 ML expected to hold largest market share of 37.7% in 2026 owing to its strong demand for high-throughput process development.
• Biopharmaceutical Companies acquired the prominent market share of 42.2% in 2026 owing to its rapid expansion of biologics pipelines. As of 2026, the United States has 3,322 biotechnology companies, representing a 4.5% increase from 2025.
• North America is expected to acquire the dominant share of 39.2% in 2026 owing to the strong biopharmaceutical industry presence.

Current Events and Their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Request Free Sample

Why is Reusable Bioreactors Acquiring the Largest Market Share?

Reusable Bioreactors hold the largest market share of 53.3% in 2026. Researchers and biopharmaceutical companies drive the adoption of reusable bioreactors in the small-scale bioreactors market due to their durability, long operational life, and suitability for repeated experimental use in process development. Biopharma firms and academic laboratories use them extensively for monoclonal antibody production, vaccine development, and cell culture studies. These systems deliver high process control, reproducibility, and effective scale-up compatibility. Growing R&D activities, the need for cost-efficient long-term equipment, and continuous improvements in bioprocess monitoring technologies further strengthen their use. In November 2025, Aber Instruments and Sartorius Stedim Biotech introduced the BioPAT Viamass single-use biomass sensor, fully integrated into Ambr 250 high-throughput single-use bioreactor vessels. They adapted Aber’s capacitance-based biomass probe into a disposable, gamma-sterilizable format that matches the performance of the reusable version and is USP Class VI compliant, compatible with Sartorius Flexsafe® systems.

5 ML-100 ML expected to hold largest market share

5 ML-100 ML expected to hold largest market share of 37.7% in 2026 owing to its growth of automation and microbioreactor platforms. Researchers and biopharmaceutical companies drive the 5 mL–100 mL segment in the small-scale bioreactors market through its extensive use in high-throughput screening, early-stage process development, and cell line optimization. They use this scale to efficiently test multiple conditions while reducing media and reagent consumption. It supports rapid experimentation in biologics, vaccines, and cell and gene therapy development. The segment further benefits from automation, advanced monitoring systems, and the demand for accurate scale-down models that enhance process understanding and improve scale-up success.

Which End User segment dominates the market?

To learn more about this report, Request Free Sample

Biopharmaceutical Companies acquired the prominent market share of 42.2% in 2026. Biopharmaceutical companies actively drive the small-scale bioreactors market by focusing on biologics such as monoclonal antibodies, vaccines, and cell and gene therapies. They use these systems for efficient cell line development, process optimization, and scale-up studies. They reduce development time and resource consumption while improving experimental accuracy through small-scale bioreactors. Companies also use them to meet regulatory requirements for process understanding and quality control. Increasing R&D investments, adoption of high-throughput technologies, and demand for flexible development platforms further strengthen their use.

Small Scale Bioreactors Market Trends

• Rising demand for high-throughput bioprocessing and parallel experimentation enhances efficiency, accelerates process optimization, and supports rapid biologics development in pharmaceutical and biotechnology industries. Global pharmaceutical R&D spending reached approximately US$300 billion in 2025, nearly double the level recorded in 2016, increasing demand for high-throughput screening and process development tools, including small-scale bioreactor systems.
• Expanding biologics pipeline, including monoclonal antibodies, vaccines, and cell and gene therapies, increases reliance on small-scale bioreactors for cell line development, screening, and scale-down studies. The U.S. FDA approved a record 55 novel drugs in 2023, with biologics and specialty therapies accounting for a significant share of approvals. Additionally, the global biologics market continues to expand, driven by strong demand for oncology, immunology, and rare disease therapies, increasing requirements for upstream process development systems.
• Rising investments in biopharmaceutical R&D and expanding contract development and manufacturing organization (CDMO) services strengthen demand for flexible and scalable small-scale bioreactor systems used in early-stage development and process validation. The United States had approximately 3,322 biotechnology companies in 2026, representing a 4.5% increase from 2025, while major CDMOs continue expanding biologics manufacturing capacity globally to support growing outsourcing requirements.

Regional Insights

To learn more about this report, Request Free Sample

North America dominates owing to rapid adoption of single-use and automated bioreactor technologies

North America is expected to acquire the dominant share of 39.20% in 2026. Biopharmaceutical companies and research organizations in North America drive the small-scale bioreactors market through a strong industry base, advanced research infrastructure, and high investment in drug development. They use small-scale bioreactors for biologics, vaccines, and cell and gene therapy research. As of February 2024, 694 cell and gene therapies (CGTs) were under development in the United States across multiple therapeutic areas. Leading pharmaceutical firms, CDMOs, and biotech startups strengthen adoption across the region. Academic and research institutions contribute through extensive bioprocess studies. Regulatory requirements for process quality, along with rapid adoption of automation and single-use technologies, further support market growth.

Asia Pacific Small Scale Bioreactors Market Trends

In Asia Pacific, expanding biopharmaceutical research drives the small scale bioreactors market along with rising demand for flexible cell culture systems. Companies increasingly adopt single-use technologies for drug development, clinical trials, vaccine research and personalized medicine, which boosts growth. Approximately 18,000 new clinical trials were registered in India in 2024, representing a 50% increase compared with 2023. Pharmaceutical firms, academic institutes and contract research organizations invest more heavily in this space, accelerating usage. Researchers emphasize regenerative medicine, infectious disease studies and cost-efficient scalable production, which encourages wider adoption across laboratories, pilot-scale manufacturing units and emerging biotechnology hubs worldwide.

United States Small Scale Bioreactors Market Trends

Strong biopharmaceutical research and development in the United States drives the small scale bioreactors market, particularly in monoclonal antibodies, cell and gene therapies, and vaccine innovation. The United States has more than 120 vaccine candidates in clinical development targeting over 40 infectious diseases. Demand for personalized medicine and the need for rapid process optimization in early-stage bioprocessing support adoption. Academic institutes, biotech companies, and contract research organizations expand collaborations and increase usage. Companies prefer single-use technologies for scalability, while regulatory expectations for efficient process development further encourage technological advancement and overall market expansion.

 In June 2026, Brooks Instrument launched the AMF Series Advanced Mass Flow Controller (MFC), an ultra-compact device that delivers high-performance gas flow measurement and control for space-limited industrial and research applications. It targets bioprocessing, lab-scale bioreactors, thin-film coating, CCUS, hydrogen technologies, analytical instruments, university labs, and industrial gas processing.

China Small Scale Bioreactors Market Trends

Rapid expansion of biopharmaceutical research and development drives the China small scale bioreactors market. Researchers and manufacturers increasingly demand flexible and cost-efficient laboratory-scale production systems. Government initiatives actively support biotechnology innovation and strengthen market growth. According to BioPharma Dive, Chinese biotechnology companies added more than 4,100 novel drug candidates to their R&D pipelines between 2022 and 2024. Academic institutions, contract research organizations, and pharmaceutical companies widely adopt these systems for process optimization and cell culture studies. Growing emphasis on vaccine development, personalized medicine, and biologics manufacturing further expands the use of small scale bioreactors across China in recent years.

Who are the Major Companies in Small Scale Bioreactors Industry

Some of the major key players in Small Scale Bioreactors are Merck KGaA, Danaher Corporation, Getinge AB, Sartorius AG,Thermo Fisher Scientific Inc., Lonza Group, Eppendorf AG, Miltenyi Biotec, Solaris Biotechnology Srl, Infors AG, Biosan, MicroDigital Co., Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf Kühner AG, Ori Biotech, Aglaris, AdvaBio

Key News

• In October 2024, Univercells Technologies launched the scale-X nexo bioreactor, a miniaturized fixed-bed bioreactor with a 0.5 m² growth surface designed for cell culture process development across multiple therapeutic modalities.

Market Report Scope

Small Scale Bioreactors Market Report Coverage

Analyst Opinion

• Small scale bioreactors are driven by the accelerating shift toward biologics and cell-based therapies rather than incremental R&D expansion alone. With biologics accounting for a major share of late-stage clinical pipelines globally, companies increasingly rely on small scale systems to de-risk scale-up before committing to large manufacturing runs, especially in monoclonal antibody and vaccine development.
• Process development efficiency is now a critical bottleneck, and small scale bioreactors are directly addressing it. In upstream bioprocessing, scale-down models are routinely used to replicate conditions of production reactors, with studies showing that well-designed small scale systems can predict large-scale performance with high correlation, reducing development cycles and minimizing costly batch failures in commercial production environments.
• Vaccine and advanced therapy production has significantly reinforced demand for controlled small scale environments. During recent global vaccine development programs, parallel bioreactor screening at small volumes enabled rapid strain selection and process optimization, with single programs often running hundreds of parallel bioreactor experiments to identify optimal yields and stability conditions before scale-up decisions are made.
• Academic and contract research organizations are expanding their reliance on automated small scale bioreactor platforms to handle high-throughput experimentation. This shift is particularly evident in cell line development workflows, where clone screening efficiency has improved substantially due to miniaturized bioreactor systems that allow tighter control of pH, dissolved oxygen, and nutrient feeding strategies at early development stages.

Market Segmentation

• By Product Type: (Revenue, USD Bn, 2021-2033)
  • Reusable Bioreactors
    • Stainless Steel Bioreactors
    • Glass Bioreactors
  • Single-use Bioreactor
• By Capacity: (Revenue, USD Bn, 2021-2033)
  • 5 ML-100 ML
  • 100 ML-250ML
  • 250ML-500ML
  • 500ML-1L
  • 1L-3L
  • 3L-5L
• By End User: (Revenue, USD Bn, 2021-2033)
  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations
  • Research Organizations
• By Region: (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Merck KGaA
  • Danaher Corporation
  • Getinge AB
  • Sartorius Ag
  • Thermo Fisher Scientific Inc.
  • Lonza Group
  • Eppendorf AG
  • Miltenyi Biotec
  • Solaris Biotechnology Srl
  • Infors AG
  • Biosan
  • MicroDigital Co., Ltd.
  • 2mag AG
  • MDX Biotechnik International GmbH
  • Esco Lifesciences Group
  • HiTec Zang GmbH
  • Hanil Scientific Inc.
  • Adolf Kühner AG
  • Ori Biotech
  • Aglaris
  • AdvaBio

Sources

Primary Research interviews

• Bioprocess engineers and upstream manufacturing specialists
• R&D scientists from pharmaceutical and biotechnology companies
• Academic researchers working on cell culture and fermentation systems
• Bioreactor equipment end-users in labs and pilot-scale facilities
• Quality and production managers in biomanufacturing units

Databases

• PubMed (bioprocessing and cell culture studies)
• Scopus (scientific and engineering research publications)
• Web of Science (biotechnology and bioengineering literature)
• ScienceDirect (bioprocess engineering journals and articles)
• SpringerLink (biomedical and biochemical engineering studies)
• Google Scholar (academic research aggregation)

Magazines

• BioProcess International
• Genetic Engineering & Biotechnology News (GEN)
• The Scientist
• Biotechnology Focus
• Lab Manager Magazine
• Chemical Engineering World (bioprocessing section)

Journals

• Journal of Biotechnology
• Biotechnology and Bioengineering
• Journal of Chemical Technology & Biotechnology
• Applied Microbiology and Biotechnology
• Cytotechnology
• Trends in Biotechnology

Newspapers

• The Economic Times (India – biotech and pharma coverage)
• Business Standard (life sciences and manufacturing updates)
• Financial Times (global pharma and biotech news)
• The Hindu BusinessLine (India industry developments)
• The Wall Street Journal (biopharma sector news)

Associations

• International Society for Pharmaceutical Engineering (ISPE)
• BioPhorum Operations Group
• European Federation of Biotechnology (EFB)
• Biotechnology Industry Research Assistance Council (BIRAC)
• Federation of Indian Chambers of Commerce & Industry (FICCI – life sciences division)
• Association of Biotechnology Led Enterprises (ABLE)

Public Domain sources

• World Health Organization (WHO) reports and datasets
• U.S. Food and Drug Administration (FDA) guidance documents
• European Medicines Agency (EMA) publications
• National Institutes of Health (NIH) resources
• World Bank open data (healthcare and industrial metrics)
• Government of India – Department of Biotechnology (DBT) reports

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 10 years